Recent News

• 05.01.2025 - Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right
• 05.01.2025 - Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right
• 03.18.2025 - Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results
• 03.18.2025 - Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results
• 11.27.2024 - Kronos Bio Announces CEO Transition and Reduction in Force
• 11.27.2024 - Kronos Bio Announces CEO Transition and Reduction in Force
• 11.14.2024 - Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
• 11.14.2024 - Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
• 11.13.2024 - Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
• 11.13.2024 - Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

Recent Filings

• 04.25.2025 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
• 04.10.2025 - 8-K Current report
• 03.18.2025 - 8-K Current report
• 03.18.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.18.2025 - EX-99.1 EX-99.1
• 12.27.2024 - 8-K Current report
• 11.27.2024 - 8-K Current report
• 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2024 - EFFECT Notice of Effectiveness